Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials.
Clemmons, David R
Drake, William M
Hutson, Kent R
Thorner, Michael O
Trainer, Peter J
Gagel, Robert F
AffiliationDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
MetadataShow full item record
AbstractOBJECTIVE: We examined pituitary tumor volumes in patients treated with pegvisomant for 18 months or longer, and in whom the tumors were monitored for at least 3 years. We present details on 9 of 304 patients in clinical trials with pegvisomant who experienced tumor growth within the first year of treatment. METHOD: Magnetic resonance images prior to start of pegvisomant and at last follow-up were examined in 43 patients (14% of participating patients). Twenty-nine had received prior radiation therapy (18% of irradiated patients) and all but five received somatostatin analogs between periods of pegvisomant treatment. RESULTS: At follow-up, the median tumor volume was 0.6 cc (range 0.0-19.7 cc), in comparison with 1.6 cc (0.0-19.7 cc) at baseline (P<0.001). Twenty-five patients, of which 23 received radiation therapy, had tumor volume reduction. Seventeen patients had no significant change. One patient, who had not received radiation therapy, had an increase in tumor volume from 1.61 to 1.93 cc. Of the nine patients with tumor growth, six had progressive growth before initiating pegvisomant. Two patients with stable tumors while on octreotide experienced enlargement after octreotide discontinuation but remained stable on long-term pegvisomant therapy. CONCLUSION: The present data indicate that pegvisomant does not promote tumor growth and suggest that the nine observed cases of tumor progression, which occurred within 8 months after commencing pegvisomant, are likely rebound expansions after discontinuation of somatostatin analogs and/or the natural history of aggressively growing pituitary tumors. Continued long-term surveillance of tumor volume, particularly in non-irradiated patients, is recommended.
CitationFollow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. 2008, 159 (5):517-23 Eur. J. Endocrinol.
JournalEuropean Journal of Endocrinology
- Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy.
- Authors: Frohman LA, Bonert V
- Issue date: 2007
- Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study.
- Authors: Marazuela M, Paniagua AE, Gahete MD, Lucas T, Alvarez-Escolá C, Manzanares R, Cameselle-Teijeiro J, Luque-Ramirez M, Luque RM, Fernandez-Rodriguez E, Castaño JP, Bernabeu I
- Issue date: 2011 Feb
- Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study.
- Authors: Buchfelder M, Weigel D, Droste M, Mann K, Saller B, Brübach K, Stalla GK, Bidlingmaier M, Strasburger CJ, Investigators of German Pegvisomant Observational Study.
- Issue date: 2009 Jul
- Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
- Authors: Yamaguchi H, Shimatsu A, Okayama A, Sato T
- Issue date: 2020 Feb 28
- Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
- Authors: Jawiarczyk A, Kałuzny M, Bolanowski M, Bednarek-Tupikowska G
- Issue date: 2008 Aug